Memphasys Ltd (MEM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Memphasys Ltd (MEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013364
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a life science company that develops and sells pre-cast electrophoresis gels, separations equipment and consumables, analytical software, and other biological products. The company offers gels which include tris glycine, and tris hepes. It offers buffers, stains and drying solutions. Memphasys offers proteomesep, which is a bench-top instrument capable of simultaneous charge and size separation of complex protein mixtures. The company also offers LA reagents and general reagents. It caters to therapeutic plasma, IVF clinical, and research consumables markets. The company operates in Australia, Singapore and the US. Memphasys is headquartered in Homebush West, New South Wales, Australia.

Memphasys Ltd (MEM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Memphasys Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Equity Offering 11
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Debt Offering 21
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Asset Transactions 22
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
Acquisition 23
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd – Key Competitors 24
Memphasys Ltd – Key Employees 25
Memphasys Ltd – Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Memphasys Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd, Key Competitors 24
Memphasys Ltd, Key Employees 25

★海外企業調査レポート[Memphasys Ltd (MEM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Burger-In Oy:企業の戦略・SWOT・財務分析
    Burger-In Oy - Strategy, SWOT and Corporate Finance Report Summary Burger-In Oy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cancer Genetics Inc (CGIX):企業の財務・戦略的SWOT分析
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic info …
  • Logicor Europe Ltd:企業の戦略的SWOT分析
    Logicor Europe Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • NorthStar Realty Finance Corp:企業のM&A・事業提携・投資動向
    NorthStar Realty Finance Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NorthStar Realty Finance Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Biafo Industries Ltd (BIFO):企業の財務・戦略的SWOT分析
    Biafo Industries Ltd (BIFO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • nib Holdings Ltd:企業の戦略・SWOT・財務分析
    nib Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary nib Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Paramo AS:企業の戦略的SWOT分析
    Paramo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Huesker Synthetic Gmbh
    Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Meridian Bancorp Inc (EBSB):企業の財務・戦略的SWOT分析
    Meridian Bancorp Inc (EBSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Damac Real Estate Development Ltd
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cairn Energy Plc (CNE):企業の財務・戦略的SWOT分析
    Cairn Energy Plc (CNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Golden Spread Electric Cooperative Inc:企業の戦略的SWOT分析
    Golden Spread Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • EnBW Energie Baden-Wuerttenberg AG:戦略・SWOT・企業財務分析
    EnBW Energie Baden-Wuerttenberg AG - Strategy, SWOT and Corporate Finance Report Summary EnBW Energie Baden-Wuerttenberg AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Nordex SE (NDX1):企業の財務・戦略的SWOT分析
    Nordex SE (NDX1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Fomento de Construcciones y Contratas SA (FCC):企業の財務・戦略的SWOT分析
    Fomento de Construcciones y Contratas SA (FCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Abion Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Abion Inc (Abion) is a biopharmaceutical company that conducts research activities to develop biopharmaceutical drugs and companion diagnostic systems for the treatment of incurable diseases. The company offers preclinical phase products such as ABN101, ABN301, ABN302, ABN401, and others. It …
  • Development Bank of Southern Africa:企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • ABO Wind AG:電力:M&Aディール及び事業提携情報
    Summary ABO Wind AG (ABO Wind) develops renewable energy projects in Europe. The company carries out the planning and environmental impact assessment, design, development, and operation of wind power projects and biomass power generating facilities. ABO Wind also provides long-term management or mai …
  • Ratnamani Metals and Tubes Ltd:企業の戦略・SWOT・財務情報
    Ratnamani Metals and Tubes Ltd - Strategy, SWOT and Corporate Finance Report Summary Ratnamani Metals and Tubes Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Koninklijke Philips N.V. (PHIA)-医療機器分野:企業M&A・提携分析
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆